Abstract P072 – Table 1. Proportion of HIV strains with resistance‐associated drugs (RAMs) at baseline, from history of RNA genotypes for each patient

NRTIs		NNRTIs		PIs		INSTIs
Lamivudine/emtricitabine	14/16 (88%)	Nevirapine	11/16 (69%)	Lopinavir/r	2/16 (13%)	Raltegravir	3/9 (33%)
Abacavir	14/16 (88%)	Efavirenz	11/16 (69%)	Atazanavir/r	3/16 (19%)	Elvitegravir/c	4/9 (44%)
Tenofovir	10/16 (63%)	Rilpivirine	11/16 (69%)	Darunavir/r QD	2/16 (13%)	Dolutegravir QD	3/9 (33%)
		Etravirine	10/16 (63%)	Darunavir/r BID	1/16 (6%)	Dolutegravir BID	1/9 (11%)

Data are given as Number of HIV strains with RAMs / Number of patients with availabe genotype(s) for analysis (%). ANRS algorithm, v.28, April 2018, was used to perfom the analysis. BID  =  twice a day (600 mg 2/d for darunavir/r and 50 mg 2/d for dolutegravir); QD  =  once a day (800 mg 1/d for darunavir/r and 50 mg 1/d for dolutegravir).